Background Frequently SARS-CoV-2 results in mild or moderate disease with potentially lower concentrations of antibodies compared to those that are hospitalised . Here, we validated an ELISA using SARS-CoV-2 trimeric spike glycoprotein, with targeted detection of IgG, IgA and IgM (IgGAM) using serum and dried blood spots (DBS) from adults with mild or moderate disease . Methods Targeting the SARS-CoV-2 trimeric spike, a combined anti-IgG, IgA and IgM serology ELISA assay was developed using 62 PCR-confirmed non-hospitalised, mild or moderate COVID-19 samples, ≥14 days post symptom onset and 624 COVID-19 negative samples . The assay was validated using 73 PCR-confirmed non-hospitalised, mild or moderate COVID-19 samples, ≥14 days post symptom onset and 359 COVID-19 negative serum samples with an additional 81 DBSs . The assay was further validated in 226 PCR-confirmed non-hospitalised, mild or moderate COVID-19 samples, ≥14 days post symptom onset and 426 COVID-19 negative clinical samples . Results A sensitivity and specificity of 98.6% (95% CI , 92.6–100.0), 98.3% (95% CI , 96.4–99.4), respectively, was observed following validation of the SARS-CoV-2 ELISA . No cross-reactivities with endemic coronaviruses or other human viruses were observed, and no change in results were recorded for interfering substances . The assay was stable at temperature extremes and components were stable for 15 days once opened . A matrix comparison showed DBS to correlate with serum results . Clinical validation of the assay reported a sensitivity of 94.7% (95% CI , 90.9–97.2 %) and a specificity of 98.4% (95% CI , 96.6–99.3 %). Conclusions The human anti-IgGAM SARS-CoV-2 ELISA provides accurate and sensitive detection of SARS-CoV-2 antibodies in non-hospitalised adults with mild or moderate disease. The use of dried blood spots makes the assay accessible to the wider community.